On the public citation graph

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group

0 signed · 310 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cpt.113openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

inferredcites →https://doi.org/10.1002/cpt.147openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

inferredcites →https://doi.org/10.1002/cpt.269openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

inferredcites →https://doi.org/10.1002/cpt.583openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

inferredcites →https://doi.org/10.1002/cpt.597openalex-snapshot

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

inferredcites →https://doi.org/10.1002/cpt.602openalex-snapshot

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

inferredcites →https://doi.org/10.1002/cpt.668openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

inferredcites →https://doi.org/10.1002/cpt.953openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

inferredcites →https://doi.org/10.1007/bf00562059openalex-snapshot

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

inferredcites →https://doi.org/10.1007/bf02293275openalex-snapshot

Informatorium Medicamentorum 1979

inferredcites →https://doi.org/10.1007/s00210-003-0832-2openalex-snapshot

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

inferredcites →https://doi.org/10.1007/s00228-006-0250-8openalex-snapshot

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

inferredcites →https://doi.org/10.1007/s00228-008-0529-zopenalex-snapshot

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

inferredcites →https://doi.org/10.1016/s0140-6736(77)91430-1openalex-snapshot

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

inferredcites →https://doi.org/10.1016/s1470-2045(10)70097-8openalex-snapshot

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism

inferredcites →https://doi.org/10.1034/j.1600-0447.2001.00299.xopenalex-snapshot

CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages

inferredcites →https://doi.org/10.1038/clpt.1985.235openalex-snapshot

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

inferredcites →https://doi.org/10.1038/clpt.2010.279openalex-snapshot

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

inferredcites →https://doi.org/10.1038/clpt.2010.320openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing

inferredcites →https://doi.org/10.1038/clpt.2011.132openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

inferredcites →https://doi.org/10.1038/clpt.2011.185openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

inferredcites →https://doi.org/10.1038/clpt.2011.269openalex-snapshot

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

inferredcites →https://doi.org/10.1038/clpt.2011.287openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

inferredcites →https://doi.org/10.1038/clpt.2011.34openalex-snapshot

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

inferredcites →https://doi.org/10.1038/clpt.2011.355openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

inferredcites →https://doi.org/10.1038/clpt.2012.209openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing

inferredcites →https://doi.org/10.1038/clpt.2012.57openalex-snapshot

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

inferredcites →https://doi.org/10.1038/clpt.2012.96openalex-snapshot

Pharmacogenomics Knowledge for Personalized Medicine

inferredcites →https://doi.org/10.1038/clpt.2013.103openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing

inferredcites →https://doi.org/10.1038/clpt.2013.105openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

inferredcites →https://doi.org/10.1038/clpt.2013.172openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

inferredcites →https://doi.org/10.1038/clpt.2013.2openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

inferredcites →https://doi.org/10.1038/clpt.2013.203openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens

inferredcites →https://doi.org/10.1038/clpt.2013.254openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

inferredcites →https://doi.org/10.1038/clpt.2013.4openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

inferredcites →https://doi.org/10.1038/clpt.2014.125openalex-snapshot

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

inferredcites →https://doi.org/10.1038/clpt.2014.159openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

inferredcites →https://doi.org/10.1038/clpt.2014.38openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update

inferredcites →https://doi.org/10.1038/clpt.2014.54openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype

inferredcites →https://doi.org/10.1038/clpt.2014.97openalex-snapshot

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

inferredcites →https://doi.org/10.1038/gim.2016.87openalex-snapshot

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

inferredcites →https://doi.org/10.1038/sj.clpt.6100291openalex-snapshot

Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients

inferredcites →https://doi.org/10.1038/sj.clpt.6100406openalex-snapshot

The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype

inferredcites →https://doi.org/10.1038/sj.clpt.6100507openalex-snapshot

Pharmacogenetics: From Bench to Byte

inferredcites →https://doi.org/10.1038/sj.mp.4001494openalex-snapshot

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

inferredcites →https://doi.org/10.1038/tpj.2009.50openalex-snapshot

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

inferredcites →https://doi.org/10.1038/tpj.2010.39openalex-snapshot

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients

inferredcites →https://doi.org/10.1067/mcp.2002.125783openalex-snapshot

Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black Americans

inferredcites →https://doi.org/10.1067/mcp.2002.127494openalex-snapshot

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

inferredcites →https://doi.org/10.1097/00008571-200010000-00001openalex-snapshot

Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6

inferredcites →https://doi.org/10.1097/00008571-200110000-00004openalex-snapshot

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6

inferredcites →https://doi.org/10.1097/00008571-200210000-00010openalex-snapshot

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

inferredcites →https://doi.org/10.1097/00008571-200211000-00011openalex-snapshot

New allelic arrangement CYP2D6*36??2 found in a Japanese poor metabolizer of debrisoquine

inferredcites →https://doi.org/10.1097/01.fpc.0000114759.08559.51openalex-snapshot

Discovery of new potentially defective alleles of human CYP2C9

inferredcites →https://doi.org/10.1097/01.fpc.0000174787.92861.91openalex-snapshot

CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population

inferredcites →https://doi.org/10.1097/01.jcp.0000088909.24613.92openalex-snapshot

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

inferredcites →https://doi.org/10.1097/01213011-199912000-00004openalex-snapshot

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

inferredcites →https://doi.org/10.1097/fpc.0b013e32834ff6e3openalex-snapshot

The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting

inferredcites →https://doi.org/10.1111/j.1365-2125.2008.03104.xopenalex-snapshot

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

inferredcites →https://doi.org/10.1111/j.1365-2125.2009.03578.xopenalex-snapshot

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

inferredcites →https://doi.org/10.1124/dmd.105.008292openalex-snapshot

CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS

inferredcites →https://doi.org/10.1177/0269881110370504openalex-snapshot

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics

inferredcites →https://doi.org/10.1371/journal.pmed.0040209openalex-snapshot

Translating Pharmacogenomics: Challenges on the Road to the Clinic

inferredcites →https://doi.org/10.1373/49.4.542openalex-snapshot

Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships

inferredcites →https://doi.org/10.1517/17425255.2015.1111871openalex-snapshot

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes

inferredcites →https://doi.org/10.2133/dmpk.21.208openalex-snapshot

Sequence-based Analysis of the CYP2D6*36-CYP2D6*10 Tandem-type Arrangement, a Major CYP2D6*10 Haplotype in the Japanese Population

inferredcites →https://doi.org/10.2133/dmpk.21.395openalex-snapshot

Diverse Structures of Chimeric CYP-REP7/6-Containing CYP2D6 and a Novel Defective CYP2D6 Haplotype Harboring Single-type *36 and CYP-REP7/6 in Japanese

inferredcites →https://doi.org/10.2146/ajhp150977openalex-snapshot

Evidence and resources to implement pharmacogenetic knowledge for precision medicine

inferredcites →https://doi.org/10.2165/00002018-200528120-00007openalex-snapshot

Clinical Relevance of Drug-Drug Interactions

inferredcites →https://doi.org/10.2174/1389200215666140130124910openalex-snapshot

Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process

inferredcites →https://doi.org/10.2174/1389200215666140202215316openalex-snapshot

Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization

inferredcites →https://doi.org/10.2217/pgs.09.71openalex-snapshot

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing

inferredcites →https://doi.org/10.2217/pgs.15.70openalex-snapshot

Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4758162openalex-extracted

Computational Exploration of Small Molecules as Inhibitor Targeting Cytochrome P4502d6

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.27909openalex-snapshot

Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia

inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.12443openalex-snapshot

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder

inferred← citeshttps://doi.org/10.1002/cpt.1035openalex-snapshot

Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome

inferred← citeshttps://doi.org/10.1002/cpt.1049openalex-snapshot

Pharmacogenetic Information in Clinical Guidelines: The European Perspective

inferred← citeshttps://doi.org/10.1002/cpt.1052openalex-snapshot

Significance of Pharmacogenomics in Precision Medicine

inferred← citeshttps://doi.org/10.1002/cpt.1279openalex-snapshot

Essential Characteristics of Pharmacogenomics Study Publications

inferred← citeshttps://doi.org/10.1002/cpt.1435openalex-snapshot

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation

inferred← citeshttps://doi.org/10.1002/cpt.1489openalex-snapshot

Development of the PG x‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing

inferred← citeshttps://doi.org/10.1002/cpt.1494openalex-snapshot

Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers

inferred← citeshttps://doi.org/10.1002/cpt.1511openalex-snapshot

Pharmacogenetics: Chasing Perfection

inferred← citeshttps://doi.org/10.1002/cpt.1665openalex-snapshot

Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics

inferred← citeshttps://doi.org/10.1002/cpt.1720openalex-snapshot

Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements

inferred← citeshttps://doi.org/10.1002/cpt.2111openalex-snapshot

Physiologically Based Precision Dosing Approach for Drug‐Drug‐Gene Interactions: A Simvastatin Network Analysis

inferred← citeshttps://doi.org/10.1002/cpt.3599openalex-snapshot

Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module

inferred← citeshttps://doi.org/10.1002/cpt.3749openalex-snapshot

Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study

inferred← citeshttps://doi.org/10.1002/cpt.70005openalex-snapshot

Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC )

inferred← citeshttps://doi.org/10.1002/epi.70279openalex-snapshot

Pharmacogenomics in epilepsy care across Asia

inferred← citeshttps://doi.org/10.1002/pcn5.1openalex-snapshot

Precision medicine in mood disorders

inferred← citeshttps://doi.org/10.1002/pcn5.26openalex-snapshot

Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic

inferred← citeshttps://doi.org/10.1002/prp2.1150openalex-snapshot

A systematic review of knowledge, attitude and practice of pharmacogenomics in pediatric oncology patients

inferred← citeshttps://doi.org/10.1002/prp2.1182openalex-snapshot

Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors

inferred← citeshttps://doi.org/10.1002/prp2.419openalex-snapshot

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6 , CYP2B6 , and CYP3A4 genotype

inferred← citeshttps://doi.org/10.1002/psp4.12563openalex-snapshot

Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype‐Derived Activity Scores

inferred← citeshttps://doi.org/10.1007/16833_2024_346openalex-snapshot

Pharmacogenomics of Cancer Chemotherapy: Transporter Polymorphisms and Drug Response

inferred← citeshttps://doi.org/10.1007/978-3-031-32035-4_147-1openalex-snapshot

Selected Genetic Polymorphisms in Psychiatry

inferred← citeshttps://doi.org/10.1007/978-3-031-32035-4_147-2openalex-snapshot

Selected Genetic Polymorphisms in Psychiatry

inferred← citeshttps://doi.org/10.1007/978-3-031-42782-4_42openalex-snapshot

The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population

inferred← citeshttps://doi.org/10.1007/978-3-031-73368-0_147openalex-snapshot

Selected Genetic Polymorphisms in Psychiatry

inferred← citeshttps://doi.org/10.1007/s00439-021-02282-3openalex-snapshot

Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG)

inferred← citeshttps://doi.org/10.1007/s00702-018-1922-0openalex-snapshot

An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes

inferred← citeshttps://doi.org/10.1007/s00737-025-01665-zopenalex-snapshot

Trimesters induced changes in pharmacokinetic parameters of antipsychotics

inferred← citeshttps://doi.org/10.1007/s10557-021-07149-3openalex-snapshot

The Interface of Therapeutics and Genomics in Cardiovascular Medicine

inferred← citeshttps://doi.org/10.1007/s11095-021-03024-wopenalex-snapshot

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

inferred← citeshttps://doi.org/10.1007/s11845-022-03112-9openalex-snapshot

Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions

inferred← citeshttps://doi.org/10.1007/s11920-020-01145-4openalex-snapshot

Pharmacogenomics: an Update for Child and Adolescent Psychiatry

inferred← citeshttps://doi.org/10.1007/s40199-024-00538-7openalex-snapshot

Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population

inferred← citeshttps://doi.org/10.1007/s40291-021-00575-xopenalex-snapshot

The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients

inferred← citeshttps://doi.org/10.1007/s40801-019-00177-4openalex-snapshot

Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study

inferred← citeshttps://doi.org/10.1007/s44361-025-00001-5openalex-snapshot

Awareness of pharmacogenomic capabilities among physicians and pharmacists in Saudi Arabia within current clinical practice

inferred← citeshttps://doi.org/10.1016/b978-0-12-812626-4.00015-2openalex-snapshot

Pharmacogenomics Education and Clinical Practice Guidelines

inferred← citeshttps://doi.org/10.1016/b978-0-12-813176-3.00036-5openalex-snapshot

Genetic testing in psychiatry: State of the evidence

inferred← citeshttps://doi.org/10.1016/b978-0-12-813695-9.00006-6openalex-snapshot

Pharmacogenomics in Clinical Care: Implications for Public Health

inferred← citeshttps://doi.org/10.1016/b978-0-12-814425-1.00021-8openalex-snapshot

Pharmacogenomics and drug metabolism

inferred← citeshttps://doi.org/10.1016/b978-0-12-819178-1.00022-8openalex-snapshot

Current status of cancer pharmacogenomics

inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00159-6openalex-snapshot

Pharmacogenomics of Anti-Cancer Drugs

inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00166-3openalex-snapshot

Computational Methods and Approaches in Pharmacogenomic Research

inferred← citeshttps://doi.org/10.1016/b978-0-12-824010-6.00053-8openalex-snapshot

Trends and implementation of preemptive pharmacogenomic testing

inferred← citeshttps://doi.org/10.1016/b978-0-323-95120-3.00008-7openalex-snapshot

Polymorphisms in drug-metabolizing enzymes: Challenges and strategies

inferred← citeshttps://doi.org/10.1016/b978-0-443-15336-5.00010-5openalex-snapshot

Basics of pharmacogenomics

inferred← citeshttps://doi.org/10.1016/b978-0-443-15336-5.00013-0openalex-snapshot

Pharmacogenomics of pulmonary and respiratory diseases

inferred← citeshttps://doi.org/10.1016/b978-0-444-64066-6.00014-9openalex-snapshot

Pharmacogenomics

inferred← citeshttps://doi.org/10.1016/bs.apha.2018.04.003openalex-snapshot

Implementation of Pharmacogenomics in Everyday Clinical Settings

inferred← citeshttps://doi.org/10.1016/bs.apha.2018.04.007openalex-snapshot

Cytochrome P450 in Pharmacogenetics: An Update

inferred← citeshttps://doi.org/10.1016/j.ajhg.2021.03.003openalex-snapshot

Opportunities and challenges for the computational interpretation of rare variation in clinically important genes

inferred← citeshttps://doi.org/10.1016/j.drup.2018.07.001openalex-snapshot

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation

inferred← citeshttps://doi.org/10.1016/j.encep.2021.12.008openalex-snapshot

Pharmacogénétique des cytochromes appliquée à la prescription des antidépresseurs : mode d’emploi

inferred← citeshttps://doi.org/10.1016/j.japh.2022.09.002openalex-snapshot

Implementing comprehensive pharmacogenomics in a community hospital–associated primary care setting

inferred← citeshttps://doi.org/10.1016/j.jmoldx.2025.11.007openalex-snapshot

Allele, Diplotype, and Phenotype Frequency Distribution of CYP2B6, CYP2C19, and CYP2D6 in the Han Population in North China

inferred← citeshttps://doi.org/10.1016/j.jsps.2022.06.013openalex-snapshot

Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard

inferred← citeshttps://doi.org/10.1016/j.nurpra.2018.09.021openalex-snapshot

Pharmacogenetics and Practice: Tailoring Prescribing for Safety and Effectiveness

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2019.01.002openalex-snapshot

Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

inferred← citeshttps://doi.org/10.1016/j.phrs.2019.104590openalex-snapshot

Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia

inferred← citeshttps://doi.org/10.1016/j.phrs.2021.105538openalex-snapshot

Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data

inferred← citeshttps://doi.org/10.1016/j.pnpbp.2025.111363openalex-snapshot

Sex and age effects on prevalence of CYP2C19 and CYP2D6 Phenoconversion risk over time in patients with psychosis

inferred← citeshttps://doi.org/10.1016/j.psychres.2020.113336openalex-snapshot

Pharmacogenetics in psychiatric care, a call for uptake of available applications

inferred← citeshttps://doi.org/10.1016/j.rmclc.2022.03.007openalex-snapshot

Uso de la farmacogenética como herramienta de precisión en psiquiatría: hacia una medicina personalizada

inferred← citeshttps://doi.org/10.1016/j.therap.2023.07.002openalex-snapshot

Experience and expectations of pharmacogenetic tests in France

inferred← citeshttps://doi.org/10.1016/s0140-6736(19)31276-0openalex-snapshot

Pharmacogenomics

inferred← citeshttps://doi.org/10.1016/s0140-6736(22)01841-4openalex-snapshot

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

inferred← citeshttps://doi.org/10.1016/s0140-6736(22)02461-8openalex-snapshot

Clinical use of pre-emptive pharmacogenetic programmes

inferred← citeshttps://doi.org/10.1016/s0140-6736(23)00852-8openalex-snapshot

The PREPARE study: benefits of pharmacogenetic testing are unclear – Authors' reply

inferred← citeshttps://doi.org/10.1016/s1470-2045(18)30686-7openalex-snapshot

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

inferred← citeshttps://doi.org/10.1038/s41380-021-01340-6openalex-snapshot

Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application

inferred← citeshttps://doi.org/10.1038/s41397-021-00260-6openalex-snapshot

Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review

inferred← citeshttps://doi.org/10.1038/s41397-022-00267-7openalex-snapshot

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study

inferred← citeshttps://doi.org/10.1038/s41397-022-00280-wopenalex-snapshot

Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patients

inferred← citeshttps://doi.org/10.1038/s41397-025-00362-5openalex-snapshot

The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study

inferred← citeshttps://doi.org/10.1038/s41397-025-00371-4openalex-snapshot

Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services

inferred← citeshttps://doi.org/10.1038/s41397-026-00400-wopenalex-snapshot

Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 2024

inferred← citeshttps://doi.org/10.1038/s41431-019-0480-8openalex-snapshot

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe

inferred← citeshttps://doi.org/10.1038/s41431-019-0540-0openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines

inferred← citeshttps://doi.org/10.1038/s41431-021-00920-yopenalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

inferred← citeshttps://doi.org/10.1038/s41431-021-01004-7openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

inferred← citeshttps://doi.org/10.1038/s41431-022-01180-0openalex-snapshot

Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate

inferred← citeshttps://doi.org/10.1038/s41431-022-01262-zopenalex-snapshot

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate

inferred← citeshttps://doi.org/10.1038/s41431-024-01572-4openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs

inferred← citeshttps://doi.org/10.1038/s41431-024-01648-1openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants

inferred← citeshttps://doi.org/10.1038/s41431-024-01769-7openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas

inferred← citeshttps://doi.org/10.1038/s41431-025-02008-3openalex-snapshot

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and CYP2C19 and tricyclic antidepressants

inferred← citeshttps://doi.org/10.1038/s41525-018-0065-4openalex-snapshot

User considerations in assessing pharmacogenomic tests and their clinical support tools

inferred← citeshttps://doi.org/10.1038/s41525-020-00156-7openalex-snapshot

Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources

inferred← citeshttps://doi.org/10.1038/s41525-022-00283-3openalex-snapshot

Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data

inferred← citeshttps://doi.org/10.1038/s41598-025-22941-zopenalex-snapshot

Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping

inferred← citeshttps://doi.org/10.1080/10408363.2023.2255279openalex-snapshot

Implementation of pharmacogenomics testing for precision medicine

inferred← citeshttps://doi.org/10.1080/13651501.2020.1809680openalex-snapshot

Precision psychiatry in clinical practice

inferred← citeshttps://doi.org/10.1080/14622416.2026.2686866openalex-snapshot

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use

inferred← citeshttps://doi.org/10.1080/15360288.2020.1734140openalex-snapshot

Improving Pain Management with Pharmacogenomics: A General Introduction

inferred← citeshttps://doi.org/10.1080/17476348.2019.1601559openalex-snapshot

Pharmacogenomics of chronic obstructive pulmonary disease

inferred← citeshttps://doi.org/10.1089/jpm.2021.0270openalex-snapshot

Feasibility and Acceptability of a Pharmacogenomic Decision Support System in Palliative Care

inferred← citeshttps://doi.org/10.1089/omi.2022.0097openalex-snapshot

Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean

inferred← citeshttps://doi.org/10.1093/ajhp/zxaa303openalex-snapshot

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

inferred← citeshttps://doi.org/10.1093/ajhp/zxac064openalex-snapshot

Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines

inferred← citeshttps://doi.org/10.1093/ehjcvp/pvab018openalex-snapshot

The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

inferred← citeshttps://doi.org/10.1093/fampra/cmac124openalex-snapshot

Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore

inferred← citeshttps://doi.org/10.1093/infdis/jiz386openalex-snapshot

Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population

inferred← citeshttps://doi.org/10.1093/jamia/ocy005openalex-snapshot

Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000430openalex-snapshot

Pharmacogenetics: a perspective and preparedness of Pharm-D and medical students in Jordan

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000438openalex-snapshot

Analytical validation of a laboratory-development multigene pharmacogenetic assay

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000452openalex-snapshot

Comparison of clinical pharmacogenetic recommendations across therapeutic areas

inferred← citeshttps://doi.org/10.1097/fpc.0000000000000467openalex-snapshot

Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry

inferred← citeshttps://doi.org/10.1097/jcp.0000000000001129openalex-snapshot

Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine

inferred← citeshttps://doi.org/10.1097/md.0000000000024545openalex-snapshot

Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism

inferred← citeshttps://doi.org/10.1101/2024.08.14.24311970openalex-snapshot

Pharmacogenomic Drug-Gene Interactions in Geriatric Emergency Department Patients That Have Fallen

inferred← citeshttps://doi.org/10.1101/2025.05.05.25326970openalex-snapshot

Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping

inferred← citeshttps://doi.org/10.1111/1440-1681.13097openalex-snapshot

Pharmacogenomics guidelines: Current status and future development

inferred← citeshttps://doi.org/10.1111/bcp.13999openalex-snapshot

Implementation and obstacles of pharmacogenetics in clinical practice: An international survey

inferred← citeshttps://doi.org/10.1111/bcp.14247openalex-snapshot

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis

inferred← citeshttps://doi.org/10.1111/bcp.14407openalex-snapshot

Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response

inferred← citeshttps://doi.org/10.1111/bcp.14704openalex-snapshot

Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK

inferred← citeshttps://doi.org/10.1111/bcp.15181openalex-snapshot

Pharmacogenomic testing in paediatrics: Clinical implementation strategies

inferred← citeshttps://doi.org/10.1111/bcp.15591openalex-snapshot

Implementation of pharmacogenomics: Where are we now?

inferred← citeshttps://doi.org/10.1111/bcp.15956openalex-snapshot

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?

inferred← citeshttps://doi.org/10.1111/bcp.16122openalex-snapshot

Estimating the prevalence of potential and actionable drug‐gene interactions in Irish primary care: A cross‐sectional study

inferred← citeshttps://doi.org/10.1111/bcpt.13196openalex-snapshot

Pharmacogenomics research and clinical implementation in Brazil

inferred← citeshttps://doi.org/10.1111/bcpt.13336openalex-snapshot

One non‐believer: Response to “Obviously Nine Believers: Actionable Germline Genetic Variants for Pre‐emptive Pharmacogenetic Testing”

inferred← citeshttps://doi.org/10.1111/bcpt.70009openalex-snapshot

Predictive Biomarkers and Personalized Therapy: Use of Pharmacogenetic Testing in a Scandinavian Perspective

inferred← citeshttps://doi.org/10.1111/cts.12692openalex-snapshot

Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

inferred← citeshttps://doi.org/10.1111/cts.12768openalex-snapshot

Primary Care Prescription Drug Use and Related Actionable Drug‐Gene Interactions in the Danish Population

inferred← citeshttps://doi.org/10.1111/cts.70009openalex-snapshot

Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study

inferred← citeshttps://doi.org/10.1111/cts.70246openalex-snapshot

Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort

inferred← citeshttps://doi.org/10.1111/iji.70052openalex-snapshot

Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine—Current Status and Future Prospects

inferred← citeshttps://doi.org/10.1111/imj.70538openalex-snapshot

Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines

inferred← citeshttps://doi.org/10.1111/jpc.70239openalex-snapshot

Real‐World Applications of Pharmacogenomics in Paediatrics

inferred← citeshttps://doi.org/10.1136/bmjopen-2019-032624openalex-snapshot

Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR

inferred← citeshttps://doi.org/10.1136/bmjopen-2024-085115openalex-snapshot

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation

inferred← citeshttps://doi.org/10.1145/3498731.3498740openalex-snapshot

Frequencies of Clinically Important CYP2C19 and CYP2D6 Alleles across East Asian populations

inferred← citeshttps://doi.org/10.1146/annurev-genom-111621-102737openalex-snapshot

Advancing Pharmacogenomics from Single-Gene to Preemptive Testing

inferred← citeshttps://doi.org/10.1158/1055-9965.epi-24-0755openalex-snapshot

CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis

inferred← citeshttps://doi.org/10.1161/circresaha.117.310965openalex-snapshot

Opportunities and Challenges in Cardiovascular Pharmacogenomics

inferred← citeshttps://doi.org/10.1177/02698811231152748openalex-snapshot

Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a role? A UK population-based study

inferred← citeshttps://doi.org/10.1177/1060028020948174openalex-snapshot

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review

inferred← citeshttps://doi.org/10.1177/1060028020983049openalex-snapshot

Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations

inferred← citeshttps://doi.org/10.1177/20420986241303432openalex-snapshot

Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment

inferred← citeshttps://doi.org/10.1177/26330040231204643openalex-snapshot

Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington’s disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics

inferred← citeshttps://doi.org/10.1186/s12888-021-03490-xopenalex-snapshot

Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands

inferred← citeshttps://doi.org/10.1186/s12888-024-06104-4openalex-snapshot

Pharmacogenomics-assisted treatment versus standard of care in schizophrenia: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1186/s12888-026-08198-4openalex-snapshot

The clinical value of pharmacogenomics in the pharmacotherapy of common psychiatric disorders: a macroscopic analysis based on real-world data

inferred← citeshttps://doi.org/10.1186/s12916-019-1342-5openalex-snapshot

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

inferred← citeshttps://doi.org/10.1186/s40246-019-0229-zopenalex-snapshot

Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good

inferred← citeshttps://doi.org/10.12688/verixiv.2312.1openalex-snapshot

Clinically actionable UGT1A1 variants in black Zimbabwean cancer patients eligible for irinotecan

inferred← citeshttps://doi.org/10.12793/tcp.2020.28.e18openalex-snapshot

Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels

inferred← citeshttps://doi.org/10.13040/ijpsr.0975-8232.15(9).2755-72openalex-snapshot

inferred← citeshttps://doi.org/10.1371/journal.pone.0268534openalex-snapshot

Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries

inferred← citeshttps://doi.org/10.1515/dmpt-2019-0005openalex-snapshot

Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in point

inferred← citeshttps://doi.org/10.15386/mpr-1564openalex-snapshot

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment

inferred← citeshttps://doi.org/10.18103/mra.v10i8.2934openalex-snapshot

Pharmacogenetics Implementation in Primary Care

inferred← citeshttps://doi.org/10.20517/cdr.2018.25openalex-snapshot

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

inferred← citeshttps://doi.org/10.20517/jtgg.2020.52openalex-snapshot

Important preparatory steps and clinical considerations for pharmacogenetics adoption into practice

inferred← citeshttps://doi.org/10.20944/preprints202011.0599.v1openalex-snapshot

Opportunities and Challenges for Interpreting Rare Variation in Clinically Important Genes

inferred← citeshttps://doi.org/10.21019/9781582123127.ch14openalex-snapshot

Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case

inferred← citeshttps://doi.org/10.21019/9781582123127.ch4openalex-snapshot

Chapter 4: Information Resources for Pharmacogenomics

inferred← citeshttps://doi.org/10.21019/9781582123844.ch14openalex-snapshot

Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case

inferred← citeshttps://doi.org/10.21019/9781582123844.ch28openalex-snapshot

Chapter 28: Information Resources for Pharmacogenomics

inferred← citeshttps://doi.org/10.21203/rs.3.rs-2981064/v1openalex-snapshot

Treatment of Chronic Inflammatory Diseases – The Potential of Pharmacogenetics

inferred← citeshttps://doi.org/10.2147/iprp.s180154openalex-snapshot

Pharmacogenomics In Pharmacy Practice: Current Perspectives

inferred← citeshttps://doi.org/10.2147/pgpm.s314972openalex-snapshot

Independent Community Pharmacists’ Experience in Offering Pharmacogenetic Testing

inferred← citeshttps://doi.org/10.2147/pgpm.s338601openalex-snapshot

Drug–Drug–Gene Interactions in Cardiovascular Medicine

inferred← citeshttps://doi.org/10.2196/32902openalex-snapshot

Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study

inferred← citeshttps://doi.org/10.2217/pgs-2018-0026openalex-snapshot

What do We Need to Transfer Pharmacogenetics Findings into the Clinic?

inferred← citeshttps://doi.org/10.2217/pgs-2018-0028openalex-snapshot

Standardization Can Accelerate the Adoption of Pharmacogenomics: Current Status and the Path Forward

inferred← citeshttps://doi.org/10.2217/pgs-2019-0041openalex-snapshot

Colorectal Cancer: Pharmacogenetics Support for the Correct Drug Prescription

inferred← citeshttps://doi.org/10.2217/pgs-2019-0086openalex-snapshot

The Search for Personalized Antidepressant Treatments: What have we Learned and Where are we Going

inferred← citeshttps://doi.org/10.2217/pgs-2019-0193openalex-snapshot

PARC report: A Perspective on the state of Clinical Pharmacogenomics Testing

inferred← citeshttps://doi.org/10.2217/pgs-2019-0194openalex-snapshot

PARC report: Health Outcomes and Value of Personalized Medicine Interventions: Impact on Patient Care

inferred← citeshttps://doi.org/10.2217/pgs-2020-0056openalex-snapshot

Unraveling Heterogeneity of the Clinical Pharmacogenomic Guidelines in Oncology Practice Among Major Regulatory Bodies

inferred← citeshttps://doi.org/10.2217/pgs-2020-0091openalex-snapshot

Pharmacogenomics in the Uk National Health Service: Opportunities and Challenges

inferred← citeshttps://doi.org/10.2217/pgs-2020-0152openalex-snapshot

Efficacy and Safety of Statins in Ethnic Differences: A Lesson for Application in Indigenous Australian Patient Care

inferred← citeshttps://doi.org/10.2217/pgs-2021-0032openalex-snapshot

Pharmacogenomic Testing to Support Prescribing in Primary Care: a Structured Review of Implementation Models

inferred← citeshttps://doi.org/10.2217/pgs-2021-0149openalex-snapshot

Keeping Pace with CYP2D6 Haplotype Discovery: Innovative Methods to Assign Function

inferred← citeshttps://doi.org/10.2217/pgs-2022-0013openalex-snapshot

Patients’ Perspectives of a Pharmacist-Provided Clinical Pharmacogenomics Service

inferred← citeshttps://doi.org/10.2217/pgs-2023-0020openalex-snapshot

Pharmacogenomics Implementation: “ A Little Less Conversation, a Little More Action, Please ”

inferred← citeshttps://doi.org/10.26481/dis.20230320roopenalex-snapshot

Personalized antithrombotic treatment in high-risk patients with coronary artery disease

inferred← citeshttps://doi.org/10.30773/pi.2019.06.16openalex-snapshot

Pharmacogenetics and Depression: A Critical Perspective

inferred← citeshttps://doi.org/10.3325/cmj.2024.65.383openalex-snapshot

Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review

inferred← citeshttps://doi.org/10.3384/diss.diva-152626openalex-snapshot

Forensic Toxicological Aspects of Tramadol : Focus on Enantioselective Drug Disposition and Pharmacogenetics

inferred← citeshttps://doi.org/10.3389/fgene.2019.00567openalex-snapshot

Use of Pharmacogenetic Drugs by the Dutch Population

inferred← citeshttps://doi.org/10.3389/fgene.2020.00010openalex-snapshot

Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective

inferred← citeshttps://doi.org/10.3389/fgene.2020.491895openalex-snapshot

How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

inferred← citeshttps://doi.org/10.3389/fitd.2022.845451openalex-snapshot

Influence of CYP2D6, CYP3A4 and CYP2C19 Genotypes on Recurrence of Plasmodium vivax

inferred← citeshttps://doi.org/10.3389/fmed.2022.1001876openalex-snapshot

Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB

inferred← citeshttps://doi.org/10.3389/fphar.2018.01436openalex-snapshot

Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit

inferred← citeshttps://doi.org/10.3389/fphar.2020.595219openalex-snapshot

Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

inferred← citeshttps://doi.org/10.3389/fphar.2021.711940openalex-snapshot

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone

inferred← citeshttps://doi.org/10.3389/fphar.2021.725565openalex-snapshot

Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry

inferred← citeshttps://doi.org/10.3389/fphar.2022.876392openalex-snapshot

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases

inferred← citeshttps://doi.org/10.3389/fphar.2023.1199462openalex-snapshot

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation

inferred← citeshttps://doi.org/10.3389/fphar.2024.1349203openalex-snapshot

Development and validation of a pharmacogenomics reporting workflow based on the illumina global screening array chip

inferred← citeshttps://doi.org/10.3389/fphar.2024.1500235openalex-snapshot

Comparing commercial pharmacogenetic testing results and recommendations for antidepressants with established CPIC guidelines

inferred← citeshttps://doi.org/10.3389/fphar.2025.1548991openalex-snapshot

Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis

showing the first 200 of 237 · page through all 237

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.